Inhibition of FAAH and activation of PPAR: New approaches to the treatment of cognitive dysfunction and drug addiction
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Enhancing the effects of endogenously-released cannabinoid ligands in the brain might provide therapeutic effects more safely and effectively than administering drugs that act directly at the cannabinoid receptor. Inhibitors of fatty acid amide hydrolase (FAAH) prevent the breakdown of endogenous ligands for cannabinoid receptors and peroxisome proliferator-activated receptors (PPAR), prolonging and enhancing the effects of these ligands when they are naturally released. This review considers recent research on the effects of FAAH inhibitors and PPAR activators in animal models of addiction and cognition (specifically learning and memory). These studies show that FAAH inhibitors can produce potentially therapeutic effects, some through cannabinoid receptors and some through PPAR. These effects include enhancing certain forms of learning, counteracting the rewarding effects of nicotine and alcohol, relieving symptoms of withdrawal from cannabis and other drugs, and protecting against relapse-like reinstatement of drug self-administration. Since FAAH inhibition might have a wide range of therapeutic actions but might also share some of the adverse effects of cannabis, it is noteworthy that at least one FAAH-inhibiting drug (URB597) has been found to have potentially beneficial effects but no indication of liability for abuse or dependence. Although these areas of research are new, the preliminary evidence indicates that they might lead to improved therapeutic interventions and a better understanding of the brain mechanisms underlying addiction and memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine, learning and motivation.
Wise, R. A. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1406 · Cited by 3,379 · cited 2×
“It is well-established that addictive drugs (including alcohol, nicotine, opiates, THC, and psychostimulants) activate reward-related circuitry in the mesolimbic dopamine system, elevating extracellular dopamine levels in the nucleus accumbens (Koob, 1992a, 1992b; Wise, 2004).”
BackgroundMolecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 2×
“Fatty acid amide hydrolase inhibition and addiction Inhibitors of FAAH were proposed as targets for the treatment of pain and neuropsychiatric disorders soon after FAAH was identified and characterized (Cravatt et al., 1996; Giang & Cravatt, 1997; Cravatt et al., 2001).”
BackgroundDrugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 3×
“Interest in FAAH inhibitors as potential treatments for drug addiction arose later, as it became clear that the endocannabinoid system can modulate the primary rewarding effects of many drugs of abuse (for reviews see Piomelli, 2003; Le Foll & Goldberg, 2005; Maldonado et al., 2006).”
BackgroundMethodThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Also consistent with a role of the endocannabinoid system in extinction learning, CB1 knockout mice and mice treated with rimonabant show impairments of extinction learning (Marsicano et al., 2002; Suzuki et al., 2004; Varvel et al., 2005).”
BackgroundIkemoto, S. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.05.004 · Cited by 1,477
Tzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 2×
“Finally, it should be noted that systemic injection of CB1 agonists would be expected to affect all populations of CB1 receptors, and therefore could produce CB1-mediated effects that are quite different from those produced by FAAH inhibitors or FAAH deletion, which presumably have a more specific effect, magnifying t…”
BackgroundMemory Reconsolidation and Extinction Have Distinct Temporal and Biochemical Signatures
Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., & Kida, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5491-03.2004 · Cited by 1,127
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“Unfortunately, the United States Food and Drug Administration could not approve rimonabant for clinical use due to increased risk of psychiatric side-effects like anxiety, depression, and suicidal ideation (Christensen et al., 2007; Rucker et al., 2007; Le Foll et al., 2009).”
BackgroundLo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Distribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744 · cited 2×
“Interactions between the endocannabinoid and peroxisome proliferatoractivated receptor systems Cannabinoid CB1 and CB2 receptors and all PPAR isoforms (α, β/δ and γ) are widely expressed in the central and peripheral nervous systems (Mackie, 2005; Pistis & Melis, 2010).”
BackgroundPPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641 · cited 1×
“The functions of the β/δ subtype, are less well established, but it might be involved in regulation of metabolism and differentiation of keratinocytes, adipocytes and oligodendrocytes (Matsuura et al., 1999; Jehl-Pietri et al., 2000; Saluja et al., 2001; Barish et al., 2006).”
BackgroundEndocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
The neurobiology of opioid dependence: implications for treatment
Kosten, T., & George, T. (2002) · Science & Practice Perspectives · doi:10.1151/spp021113 · Cited by 505
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Guindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406 · cited 1×
“The dose range of THC that maintained self-administration behavior in these studies (1–16 βg/kg per injection) was lower than that used in previous studies and comparable to that received from smoking a marijuana cigarette (Agurell et al., 1986; Tanda et al., 2000).”
MethodBrain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397 · cited 2×
“Recently, Xi et al. (2008, 2011) showed that blockade of CB1 receptors can inhibit cocaine-enhanced brain-stimulation Pharmacol Ther.”
BackgroundCohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396 · cited 2×
“The effect of both drugs on nicotine-induced reinstatement could be partially explained by their ability to block nicotineinduced elevations of dopamine in the nucleus accumbens shell (Cohen et al., 2002; Scherma et al., 2008c).”
BackgroundFunctional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro, M., Carrera, M. R. A., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gómez, R., del Arco, I., Villanúa, M. A., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05344.2001 · Cited by 378 · cited 3×
“There have also been several demonstrations of intravenous and intracerebroventricular self-administration of synthetic CB1 receptor agonists in rodents: WIN 55,212-2, CP 55,940, and HU-210 in mice (Martellotta et al., 1998; Ledent et al., 1999; Braida et al., 2001b; Navarro et al., 2001) and WIN 55,212-2 in rats (Fat…”
BackgroundGold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α
LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., & Piomelli, D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111385 · Cited by 316
Gunduz-Cinar, O., MacPherson, K. P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B., Godlewski, G., Ramikie, T. S., Gorka, A. X., Alapafuja, S. O., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.72 · Cited by 307
Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation
Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Fur, G. L., & Casellas, P. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.032 · Cited by 298
Caillé, S., Alvarez-Jaimes, L., Polis, I., Stouffer, D. G., & Parsons, L. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4403-06.2007 · Cited by 280 · cited 4×
“In rats, cocaineinduced enhancements in brain stimulation reward were unaffected by administration of a CB1 antagonist (Vlachou et al., 2003), as were cocaine-induced increases in nucleus accumbens dopamine levels (Caille & Parsons, 2006; Caille et al., 2007).”
BackgroundInfluentialChiang, K. P. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh216 · Cited by 278
Hill, M. N., Patel, S., Campolongo, P., Tasker, J. G., Wotjak, C. T., & Bains, J. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4283-10.2010 · Cited by 255
Hill, M. N., Kumar, S. A., Filipski, S. B., Iverson, M., Stuhr, K. L., Keith, J. M., Cravatt, B. F., Hillard, C. J., Chattarji, S., & McEwen, B. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.90 · Cited by 222
Effects of endocannabinoid system modulation on cognitive and emotional behavior
Zanettini, C. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00057 · Cited by 214
Role of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity
Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., He, J., Nitta, A., Mizuno, M., Tran, M. H., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4847-03.2004 · Cited by 176
A catalytically silent FAAH-1 variant drives anandamide transport in neurons
Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., Guijarro, A., Lodola, A., Armirotti, A., Garau, G., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.2986 · Cited by 175 · cited 5×
“Transport through the membrane may depend on certain membrane and intracellular transporters such as the FAAH-like anandamide transporter (Fu et al., 2012) and the fatty acid binding proteins FABP5 or FABP7 (Kaczocha et al., 2009; Fu et al., 2012).”
BackgroundInfluentialTwo brain sites for cannabinoid reward
Zangen, A., Solinas, M., Ikemoto, S., Goldberg, S. R., & Wise, R. A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3554-05.2006 · Cited by 174
Haller, J., Barna, I., Barsvari, B., Gyimesi Pelczer, K., Yasar, S., Panlilio, L. V., & Goldberg, S. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1494-7 · Cited by 159
Self-citationCB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats
Navarro, M., Chowen, J., Carrera, M. R. A., del Arco, I., Villanúa, M. A., Martin, Y., Roberts, A. J., Koob, G. F., & de Fonseca, F. R. (1998) · NeuroReport · doi:10.1097/00001756-199810260-00012 · Cited by 152 · cited 1×
“The cessation of regular morphine use or the administration of an opioid or cannabinoid CB1 receptor antagonist in morphine dependent individuals precipitates withdrawal symptoms with somatic and affective components (Navarro et al., 1998; Kosten & George, 2002).”
BackgroundFat-induced satiety factor oleoylethanolamide enhances memory consolidation
Campolongo, P., Roozendaal, B., Trezza, V., Cuomo, V., Astarita, G., Fu, J., McGaugh, J. L., & Piomelli, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903038106 · Cited by 133 · cited 2×
“Campolongo et al. (2009) also found evidence that PPAR-α activation can enhance learning; administration of OEA enhanced learning in both a passive-avoidance procedure and a spatial-learning procedure (water maze) in rats.”
BackgroundCandidate genes for cannabis use disorders: findings, challenges and directions.
Agrawal, A., & Lynskey, M. T. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02504.x · Cited by 128
Nuclear receptors as therapeutic targets for Alzheimer's disease
Mandrekar-Colucci, S., & Landreth, G. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.594043 · Cited by 126
Tyndale, R. F., Payne, J. I., Gerber, A. L., & Sipe, J. C. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30491 · Cited by 117 · cited 4×
“…problem drug use (Sipe et al., 2002; Flanagan et al., 2006), but further studies showed that those with the A/A genotype are not at greater risk for alcohol, nicotine, heroin or methamphetamine dependence (Morita et al., 2005; Iwasaki et al., 2007; Tyndale et al., 2007; Proudnikov et al., 2010).”
BackgroundResultInfluentialTanda, G., Munzar, P., Goldberg, S. R., & Justinova, Z. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1693-6 · Cited by 111
Self-citationMelis, M., Carta, S., Fattore, L., Tolu, S., Yasar, S., Goldberg, S. R., Fratta, W., Maskos, U., & Pistis, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.016 · Cited by 89
Self-citationManwell, L. A., Satvat, E., Lang, S. T., Allen, C. P., Leri, F., & Parker, L. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.08.002 · Cited by 48
Cited by
Endocannabinoid signalling in reward and addiction
Parsons, L. H., & Hurd, Y. L. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4004 · Cited by 481
Amygdala FAAH and anandamide: mediating protection and recovery from stress
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., & Holmes, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.008 · Cited by 229
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Boileau, I., Mansouri, E., Williams, B., Le Foll, B., Rusjan, P., Mizrahi, R., Tyndale, R. F., Huestis, M. A., Payer, D. E., Wilson, A. A., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.04.012 · Cited by 82
Metadata
- Authors
- Panlilio, L. V., Justinova, Z., & Goldberg, S. R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 138
- Issue
- 1
- Pages
- 84-102
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W1976973005
- Cited by
- 108
- References
- 44
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.